PremiumThe FlyiKena Oncology reports Q3 EPS (21c), consensus (27c) Ikena Oncology’s Gamble: Slashing Workforce by Half Could Derail Strategic Plans Ikena Oncology Promotes Jotin Marango to Chief Operating Officer PremiumThe FlyiKena discontinues IK-930 and reduces workforce by 53%, to review alternatives iKena Oncology reports Q1 EPS (33c), consensus (41c) iKena Oncology expects cash to meet operating requirements into 2H26 PremiumThe FlyIkena Oncology Inc trading resumes iKena cuts 35% of workforce to focus on IK-930 and IK-595, to extend runway Ikena Oncology Inc trading halted, news pending